Study purpose:

The primary purpose of conducting this Phase 4 post marketing study is to assess the efficacy of AXS-05 compared to Buproprion in preventing relapse of depression symptoms in subjects who have responded to treatment with AXS-05

What is the medication?

AXS-05 is Auvelity, which is a combination of Dextromethorphan hydrobromide and Bupropion hydrochloride

Overview:

Screening period: up to 4 weeks

Treatment periods:

10 week, open label AXS-05 of which there will be a 6 week response evaluation period followed by a 4 week remission evaluation and stabilization period

 26 week, double blind, randomized (AXS vs Buproprion)

Follow up period: 1 week

You May Qualify If:

You meet criteria for Major Depressive Disorder (MDD) and are currently in a Major Depressive Episode for which you are in need of treatment for MDD or a change in treatment for MDD because of suboptimal response and/or intolerance to current therapy

Qualified candidates may earn up to ____ per visit. Transportation assistance to those who enroll.